BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

...NASDAQ:AIMT) hired Narinder Singh as EVP, technical operations. He joins the food allergies company from Genocea Biosciences Inc....
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...and serves on the boards of Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Massachusetts Eye and Ear and Genocea Biosciences Inc....
BioCentury | Nov 21, 2019
Targets & Mechanisms

Genocea's cautionary tale: avoid inhibitory neoantigens in vaccines

...of neoantigens that, when presented on MHC molecules, elicit potent antitumor immune responses. According to Genocea Biosciences Inc....
...main strategies for neoantigen selection constitutes computational prediction based on genome and transcriptome data analysis. Genocea...
...Across three posters presented at the Society for Immunotherapy of Cancer (SITC) meeting this month, Genocea...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...companies with clinical-stage neoantigen vaccines -- Neon Therapeutics Inc. (NASDAQ:NTGN), Gritstone Oncology Inc. (NASDAQ:GRTS) and Genocea Biosciences Inc....
...new, interesting information emerges, we’ll continue to try to incorporate it into our pipeline,” said Genocea...
...need to be able to prime from a completely naïve T cell repertoire.” Flechtner sees Genocea’s...
BioCentury | Sep 27, 2019
Product Development

Reading into the first wave of neoantigen results

...studies in melanoma and glioblastoma patients, respectively, from academic teams led by Neon's scientific founders. Genocea Biosciences Inc....
...German biotech declined to discuss either study, citing a quiet period ahead of its IPO. Genocea Biosciences Inc....
...five or fewer patients. These case studies have primarily captured vaccine immunogenicity using ELISPOT assays. Genocea...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...6/19/19 $30.0 NA $151.8 NA Zymeworks Inc. (TSX:ZYME; NYSE:ZYME) (A) 6/19/19 $201.3 NA $861.0 NA Genocea Biosciences Inc....
BioCentury | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

...chemotherapy. Preliminary median OS was 10.8 months. Early immune response data for Genocea's neoantigen vaccine Genocea Biosciences Inc....
...HKI-272 (Compound #), Oral neratinib (Generic) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Aduro Biotech Inc. American Society of Clinical Oncology ASCO Genocea Biosciences Inc. Johnson...
BioCentury | Feb 15, 2019
Financial News

Genocea planning $39M financing

...warrants. The second is contingent on positive results from a Phase I/II trial for GEN-009, Genocea's...
...million from investors that participated in the first closing. Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Business: Cancer Mark Zipkin GEN-009 Genocea Biosciences Inc....
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...CDKL5) epilepsy on Sept. 11 and raising $40.3 million in a follow-on on Sept. 15. Genocea Biosciences Inc....
...NASDAQ:BGNE), Beijing, China BGI Genomics Co. Ltd. (SZSE:300676), Shenzhen, China Celgene Corp. (NASDAQ:CELG), Summit, N.J. Genocea Biosciences Inc....
...Senior Editor, Research & Analytics BGB-A317 ganaxolone GEN-003 GEN-009 Intepirdine ivacaftor Kalydeco Ocaliva patisiran Somavaratan tezacaftor volanesorsen VX-152 VX-440 VX-659 Vyzulta Akcea Therapeutics Inc. Alnylam Pharmaceuticals Inc. Axovant Sciences Ltd. BeiGene Ltd. BGI Genomics Co. Ltd. Celgene Corp. Genocea Biosciences Inc. Gilead...
BioCentury | Sep 29, 2017
Clinical News

Genocea discontinues HSV-2 candidate GEN-003

...ICP4) and gD2 antigens from herpes simplex virus-2 (HSV-2) combined with the saponin-derivative adjuvant Matrix-M2. Genocea...
...start a Phase I trial to treat tumors next half, with data expected in 1H19. Genocea Biosciences Inc....
...genital herpes simplex virus type 2 (HSV-2) infection Endpoint: NA Status: Development discontinued Milestone: NA Chris Lieu GEN-003 GEN-009 Genocea Biosciences Inc. Infected...
Items per page:
1 - 10 of 100
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

...NASDAQ:AIMT) hired Narinder Singh as EVP, technical operations. He joins the food allergies company from Genocea Biosciences Inc....
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...and serves on the boards of Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Massachusetts Eye and Ear and Genocea Biosciences Inc....
BioCentury | Nov 21, 2019
Targets & Mechanisms

Genocea's cautionary tale: avoid inhibitory neoantigens in vaccines

...of neoantigens that, when presented on MHC molecules, elicit potent antitumor immune responses. According to Genocea Biosciences Inc....
...main strategies for neoantigen selection constitutes computational prediction based on genome and transcriptome data analysis. Genocea...
...Across three posters presented at the Society for Immunotherapy of Cancer (SITC) meeting this month, Genocea...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...companies with clinical-stage neoantigen vaccines -- Neon Therapeutics Inc. (NASDAQ:NTGN), Gritstone Oncology Inc. (NASDAQ:GRTS) and Genocea Biosciences Inc....
...new, interesting information emerges, we’ll continue to try to incorporate it into our pipeline,” said Genocea...
...need to be able to prime from a completely naïve T cell repertoire.” Flechtner sees Genocea’s...
BioCentury | Sep 27, 2019
Product Development

Reading into the first wave of neoantigen results

...studies in melanoma and glioblastoma patients, respectively, from academic teams led by Neon's scientific founders. Genocea Biosciences Inc....
...German biotech declined to discuss either study, citing a quiet period ahead of its IPO. Genocea Biosciences Inc....
...five or fewer patients. These case studies have primarily captured vaccine immunogenicity using ELISPOT assays. Genocea...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...6/19/19 $30.0 NA $151.8 NA Zymeworks Inc. (TSX:ZYME; NYSE:ZYME) (A) 6/19/19 $201.3 NA $861.0 NA Genocea Biosciences Inc....
BioCentury | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

...chemotherapy. Preliminary median OS was 10.8 months. Early immune response data for Genocea's neoantigen vaccine Genocea Biosciences Inc....
...HKI-272 (Compound #), Oral neratinib (Generic) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Aduro Biotech Inc. American Society of Clinical Oncology ASCO Genocea Biosciences Inc. Johnson...
BioCentury | Feb 15, 2019
Financial News

Genocea planning $39M financing

...warrants. The second is contingent on positive results from a Phase I/II trial for GEN-009, Genocea's...
...million from investors that participated in the first closing. Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Business: Cancer Mark Zipkin GEN-009 Genocea Biosciences Inc....
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...CDKL5) epilepsy on Sept. 11 and raising $40.3 million in a follow-on on Sept. 15. Genocea Biosciences Inc....
...NASDAQ:BGNE), Beijing, China BGI Genomics Co. Ltd. (SZSE:300676), Shenzhen, China Celgene Corp. (NASDAQ:CELG), Summit, N.J. Genocea Biosciences Inc....
...Senior Editor, Research & Analytics BGB-A317 ganaxolone GEN-003 GEN-009 Intepirdine ivacaftor Kalydeco Ocaliva patisiran Somavaratan tezacaftor volanesorsen VX-152 VX-440 VX-659 Vyzulta Akcea Therapeutics Inc. Alnylam Pharmaceuticals Inc. Axovant Sciences Ltd. BeiGene Ltd. BGI Genomics Co. Ltd. Celgene Corp. Genocea Biosciences Inc. Gilead...
BioCentury | Sep 29, 2017
Clinical News

Genocea discontinues HSV-2 candidate GEN-003

...ICP4) and gD2 antigens from herpes simplex virus-2 (HSV-2) combined with the saponin-derivative adjuvant Matrix-M2. Genocea...
...start a Phase I trial to treat tumors next half, with data expected in 1H19. Genocea Biosciences Inc....
...genital herpes simplex virus type 2 (HSV-2) infection Endpoint: NA Status: Development discontinued Milestone: NA Chris Lieu GEN-003 GEN-009 Genocea Biosciences Inc. Infected...
Items per page:
1 - 10 of 100